FrancophonIA/ELRC3.0 huggingface dataset:
English: Pemetrexed Fresenius Kabi is a medicine used in the treatment of cancer.
Lithuanian: Che cos'è Pemetrexed Fresenius Kabi e a che cosa serve Pemetrexed Fresenius Kabi è un medicinale usato nel trattamento dei tumori.
English: If you get any side effects, talk to your doctor or pharmacist.
Lithuanian: Se ha qualsiasi dubbio, si rivolga al medico o al farmacista.
English: Leukocytes decreased Haemoglobin decreased Platelets decreased
Lithuanian: Diminuzione dei leucociti Diminuzione dell'emoglobina
English: When using Pemetrexed Fresenius Kabi in combination with cisplatin:
Lithuanian: Pemetrexed Fresenius Kabi in associazione con cisplatino
English: From the start of pemetrexed plus cisplatin first line induction treatment, the median OS of patients was 16.9 months for the pemetrexed arm and 14.0 months for the placebo arm (hazard ratio= 0.78, 95% CI= 0.64-0.96).
Lithuanian: Dall'inizio del trattamento di prima linea con pemetrexed più cisplatino (induzione), la sopravvivenza globale (OS) mediana è risultata 16,9 mesi per i pazienti nel braccio pemetrexed e 14 mesi per i pazienti nel braccio placebo (hazard ratio=0,78, 95%CI=0,64-0,96).
English: Pemetrexed Fresenius Kabi is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).
Lithuanian: Pemetrexed Fresenius Kabi è indicato in monoterapia nel trattamento di seconda linea di pazienti con carcinoma polmonare non a piccole cellule localmente avanzato o metastatico ad eccezione dell'istologia a predominanza di cellule squamose (vedere paragrafo 5.1).
English: Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory medicinal product (NSAIDs) such as ibuprofen, and acetylsalicylic acid (> 1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).
Lithuanian: Pazienti con insufficienza renale da lieve a moderata (clearance della creatinina da 45 a 79 ml/min) devono evitare di assumere farmaci antinfiammatori non steroidei (FANS) come ibuprofene e acido acetilsalicilico (> 1,3 g/die) nei 2 giorni precedenti, il giorno stesso e nei 2 giorni successivi alla somministrazione di pemetrexed (vedere paragrafo 4.5).
English: The median OS for patients with NSCLC other than predominantly squamous cell histology (n = 481) was 15.5 months for the pemetrexed arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95% CI = 0.56-0.88, p = 0.002).
Lithuanian: La OS mediana per pazienti con NSCLC ad eccezione dell'istologia a predominanza di cellule squamose (n = 481) è stata di 15,5 mesi per il braccio pemetrexed e di 10,3 mesi per il braccio placebo (hazard ratio = 0,70, 95% CI: 0,56-0,88, p = 0,002).
English: Pemetrexed/ cisplatin (N = 839)
Lithuanian: Pemetrexed/ cisplatino (N = 839)
English: Clinically relevant toxicity that was reported in < 1% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: GGT increase, chest pain, arrhythmia, and motor neuropathy.
Lithuanian: Una tossicità clinicamente rilevante, riportata in una percentuale < 1 % dei pazienti che sono stati assegnati in maniera randomizzata a ricevere cisplatino e pemetrexed, comprende: aumento della GGT, dolore toracico, aritmia, e neuropatia motoria.
English: Breastfeeding must be discontinued during Pemetrexed Fresenius Kabi treatment.
Lithuanian: L'allattamento deve essere interrotto durante il trattamento con Pemetrexed Fresenius Kabi.
English: Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Lithuanian: Una tossicità clinicamente rilevante, riportata in una percentuale ≥ 1 % e ≤ 5 % dei pazienti che sono stati assegnati in maniera randomizzata a ricevere cisplatino e pemetrexed, comprende: aumento di AST, aumento di ALT, infezione, neutropenia febbrile, insufficienza renale, piressia, disidratazione, congiuntivite, e diminuzione della clearance della creatinina.
English: Rarely, immune-mediated haemolytic anaemia has been reported in patients treated with pemetrexed.
Lithuanian: Raramente, in pazienti trattati con pemetrexed è stata riportata anemia emolitica immunomediata.
English: Concomitant administration of substances that are also tubularly secreted (e.g. probenecid, penicillin) could potentially result in delayed clearance of pemetrexed.
Lithuanian: probenecid, penicillina) potrebbero potenzialmente determinare una clearance ritardata del pemetrexed.
English: Pemetrexed Fresenius Kabi in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).
Lithuanian: Pemetrexed Fresenius Kabi in associazione con cisplatino è indicato come prima linea di trattamento di pazienti con carcinoma polmonare non a piccole cellule localmente avanzato o metastatico ad eccezione dell'istologia a predominanza di cellule squamose (vedere paragrafo
English: NeuropathySensory
Lithuanian: Neuropatia sensitiva
English: Some patients have experienced a heart attack, stroke or “mini-stroke” while receiving Pemetrexed Fresenius Kabi usually in combination with another anticancer therapy.
Lithuanian: Polmonite interstiziale (piccole cicatrici intorno agli alveoli polmonari) Edema (liquidi in eccesso nel tessuto corporeo, che causano gonfiore) Alcuni pazienti hanno avuto un attacco cardiaco, un accidente cerebrovascolare, anche di lieve entità, durante il trattamento con Pemetrexed Fresenius Kabi, di solito in associazione con un'altra terapia antitumorale.
English: Pemetrexed / Cisplatin (N = 226)
Lithuanian: Parametro di efficacia Pemetrexed / Cisplatino (N = 226)
English: Marketing Authorisation Holder
Lithuanian: Titolare dell'autorizzazione all'immissione in commercio
English: Common Constipation
Lithuanian: Comune Dispepsia
English: Clinically relevant CTC toxicities that were reported in ≥ 1 % and < 5 % of the patients that were randomly assigned to pemetrexed include: infection without neutropenia, febrile neutropenia, allergic reaction/hypersensitivity, increased creatinine, motor neuropathy, sensory neuropathy, erythema multiforme, and abdominal pain.
Lithuanian: Le tossicità CTC clinicamente rilevanti riportate in una percentuale ≥ 1 % e ≤5 % dei pazienti che sono stati assegnati in maniera randomizzata a ricevere pemetrexed, comprendono: infezione senza neutropenia, neutropenia febbrile, reazione allergica/ipersensibilità, aumento della creatininemia, neuropatia motoria, neuropatia sensitiva, eritema multiforme e dolore addominale.
English: Grade
Lithuanian: SCAD
English: Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion
Lithuanian: Pemetrexed Fresenius Kabi 100 mg polvere per concentrato per soluzione per infusione
English: An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of pemetrexed versus docetaxel for other than predominantly squamous histologies (n = 399, 9.3 versus 8.0 months, adjusted HR = 0.78; 95% CI = 0 .61-1.00, p = 0.047) and was in favour of docetaxel for squamous cell carcinoma histology (n = 172, 6.2 versus 7.4 months, adjusted HR = 1.56; 95% CI = 1.08-2.26, p = 0.018).
Lithuanian: Un'analisi dell'impatto dell'istologia del carcinoma polmonare non a piccole cellule sull'effetto del trattamento sulla sopravvivenza globale è risultata a favore di pemetrexed rispetto a docetaxel per gli istotipi a predominanza non squamosa (n = 399; 9,3 verso 8,0 mesi, HR corretto = 0,78; 95 % CI = 0,61 - 1.
English: Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion
Lithuanian: Pemetrexed Fresenius Kabi 500 mg polvere per concentrato per soluzione per infusione
English: Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion pemetrexed
Lithuanian: Foglio illustrativo: informazioni per l'utilizatore Pemetrexed Fresenius Kabi 100 mg polvere per concentrato per soluzione per infusione Pemetrexed Fresenius Kabi 500 mg polvere per concentrato per soluzione per infusione pemetrexed
English: Taste disturbance 8.1 0.0*** 8.9 0.0***
Lithuanian: Eruzione cutanea 16,1
English: Creatinine clearance decreased**
Lithuanian: Riduzione della clearance della creatinine
English: Efficacy of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma Randomised and treated patients
Lithuanian: cisplatino nel mesothelioma pleurico maligno Pazienti randomizzati e trattati Pazienti integrati per tutta la durata del trattamento
English: Common SGPT (ALT) elevation
Lithuanian: Patologie epatobiliari Comune Aumento della SGPT (ALT)
English: Rash/ desquamation Common Pruritus Alopecia
Lithuanian: Anoressia Comune Stipsi
English: Clinically relevant CTC toxicities that were reported in ≥ 1 % and < 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Lithuanian: Le tossicità CTC clinicamente rilevanti riportate in una percentuale ≥ 1 % e ≤ 5 % dei pazienti che sono stati assegnati in maniera randomizzata a ricevere cisplatino e pemetrexed, comprendono: insufficienza renale, infezione, piressia, neutropenia febbrile, aumento dei valori di AST, ALT e GGT, orticaria e dolore toracico.
English: The independent review of patient scans confirmed the findings of the investigator assessment of PFS. For randomised patients, as measured from the start of pemetrexed plus cisplatin first line induction treatment, the median investigator-assessed PFS was 6.9 months for the pemetrexed arm and 5.6 months for the placebo arm (hazard ratio = 0.59 95% CI =
Lithuanian: Per i pazienti randomizzati, quando misurati dall'inizio del trattamento di pemetrexed più cisplatino in prima linea (induzione), la PFS mediana rilevata dallo sperimentatore è stata di 6,9 mesi per il braccio pemetrexed e 5,6 mesi per il braccio placebo (hazard ratio = 0,59 95% CI = 0,47-0,74).
English: Elderly
Lithuanian: Anziani
English: Fast heart rate
Lithuanian: Aumento del battito cardiaco
English: Nausea Anorexia
Lithuanian: Nausea Vomito
English: Constipation
Lithuanian: Costipazione
English: Breast-feeding
Lithuanian: Stomatite/ faringite
English: What Pemetrexed Fresenius Kabi contains
Lithuanian: Cosa contiene Pemetrexed Fresenius Kabi
English: Reconstitute each 100 mg vial with 4.2 ml of 5% glucose intravenous infusion resulting in a solution containing 25 mg/ml pemetrexed.
Lithuanian: Ricostituire ogni flaconcino da 100 mg con 4,2 ml di soluzione di glucosio 5% per infusione endovenosa per ottenere una soluzione contenente 25 mg/ml di pemetrexed.
English: Reconstitute each 500 mg vial with 20 ml of 5% glucose intravenous infusion resulting in a solution containing 25 mg/ml pemetrexed.
Lithuanian: Ricostituire ogni flaconcino da 500 mg con 20 ml di soluzione di glucosio 5% per infusione endovenosa per ottenere una soluzione contenente 25 mg/ml di pemetrexed.
English: Reconstitute 500-mg vials with 20 ml of 5% glucose intravenous infusion resulting in a solution containing 25 mg/ml pemetrexed.
Lithuanian: Ricostituire i flaconcini da 500 mg con 20 ml di soluzione di glucosio 5% per infusione endovenosa per ottenere una soluzione contenente 25 mg/ml di pemetrexed.
English: Check with your doctor or pharmacist if you are not sure.
Lithuanian: Se ha dubbi consulti il medico o il farmacista.
English: For the purpose of this table a cut off of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.
Lithuanian: Per questa tabella è stato usato un cut-off del 5 % per l'inclusione di tutti gli eventi per i quali colui che ha riportato i dati ha considerato possibile una relazione con il pemetrexed e il cisplatino.
English: Reconstitute 100-mg vials with 4.2 ml of 5% glucose intravenous infusion resulting in a solution containing 25 mg/ml pemetrexed.
Lithuanian: Ricostituire i flaconcini da 100 mg con 4,2 ml di soluzione di glucosio 5% per infusione endovenosa per ottenere una soluzione contenente 25 mg/ml di pemetrexed.
English: ***According to National Cancer Institute CTC (v2.0; NCI 1998), taste disturbance and alopecia should only be reported as Grade 1 or 2.
Lithuanian: ** derivato dal termine “renale/genitourinario - altro”. ***In accordo con i National Cancer Institute CTC (v2.0; NCI 1998), l'alterazione del gusto e l'alopecia devono essere riportate esclusivamente come Grado 1 o 2.
English: Table 1 - Dose modification table for pemetrexed (as single agent or in combination) and cisplatin- Haematologic toxicities
Lithuanian: Tabella 1 - Tabella di variazione della dose per pemetrexed (come singolo farmaco o in associazione) e cisplatino - Tossicità ematologica ANC al nadir < 500 /mm e piastrine al nadir
English: NAME OF THE MEDICINAL PRODUCT Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion pemetrexed
Lithuanian: DENOMINAZIONE DEL MEDICINALE Pemetrexed Fresenius Kabi 500 mg polvere per concentrato per soluzione per infusione pemetrexed
English: For the purpose of this table, a cut-off of 5% was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed and cisplatin.
Lithuanian: Per questa tabella, è stato usato un cut-off del 5% al fine di includere tutti gli eventi per i quali è stata considerata una possibile relazione con il pemetrexed ed il cisplatino.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion pemetrexed
Lithuanian: DENOMINAZIONE DEL MEDICINALE E VIA DI SOMMINISTRAZIONE Pemetrexed Fresenius Kabi 100 mg polvere per concentrato per soluzione per infusione pemetrexed
English: NAME OF THE MEDICINAL PRODUCT Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion pemetrexed
Lithuanian: DENOMINAZIONE DEL MEDICINALE Pemetrexed Fresenius Kabi 100 mg polvere per concentrato per soluzione per infusione pemetrexed
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion pemetrexed
Lithuanian: DENOMINAZIONE DEL MEDICINALE E VIA DI SOMMINISTRAZIONE Pemetrexed Fresenius Kabi 500 mg polvere per concentrato per soluzione per infusione pemetrexed
English: Constipation Stomatitis/
Lithuanian: Eruzione cutanea Alopecia
English: Common Taste disturbance Eye disorders Common Conjunctivitis
Lithuanian: Eruzione cutanea/ desquamazione Comune Prurito Alopecia
English: Dehydration
Lithuanian: Disidratazione
English: For the purpose of this table a cut off of 5 % was used for inclusion of all events where the reporter considered a possible relationship to pemetrexed.
Lithuanian: Per questa tabella è stato usato un cut-off del 5 % per l'inclusione di tutti gli eventi per i quali colui che ha riportato i dati ha considerato possibile una relazione con il pemetrexed.
English: Haemoglobin decreased
Lithuanian: Diminuzione dell'emoglobin a
English: OUTER CARTON
Lithuanian: ASTUCCIO ESTERNO
English: Pharyngitis
Lithuanian: Stipsi
English: For single use only.
Lithuanian: Esclusivamente monouso.
English: Or
Lithuanian: O
English: Cytotoxic
Lithuanian: Citotossico
English: Common Dyspepsia/ Heartburn
Lithuanian: Comune Dispepsia/ Pirosi
English: The doctor or hospital pharmacist will work out the dose you need based on your height and weight.
Lithuanian: Quando Pemetrexed Fresenius Kabi è usato in associazione con cisplatino: Il medico o il farmacista ospedaliero calcolerà la dose di cui ha bisogno in base alla sua altezza e al suo peso.
English: What is in this leaflet
Lithuanian: Contenuto di questo foglio
English: PC:
Lithuanian: PC SN NN
English: 19 January 2017 EMA/747766/2016
Lithuanian: EMA/747766/2016
English: More information about Suliqua can be found on the Agency's website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004243/human_ med_002064.jsp
Lithuanian: Daugiau informacijos apie Suliqua galima rasti agentūros svetainėje adresu http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004243/hu man_med_002064.jsp
English: • If you have any questions about your treatment, speak to your healthcare professional.
Lithuanian: • Jeigu jums iškiltų klausimų dėl jums paskirto gydymo, pasitarkite su savo sveikatos priežiūros specialistu.
English: Measures intended to reduce risk of confusion between two pens of different strengths
Lithuanian: Priemonės, kuriomis siekiama sumažinti pavojų supainioti du švirkštiklius su skirtingo stiprumo vaistu
English: Your healthcare professional will give you this information.
Lithuanian: Tokią informaciją jums suteiks jūsų sveikatos priežiūros specialistas.
English: Information for patients and carers
Lithuanian: Informacija pacientams ir juos slaugantiems asmenims
English: Suliqua is a medicine that is used for the treatment of type-2 diabetes.
Lithuanian: Suliqua - tai vaistas, kuriuo gydomas 2 tipo diabetas.
English: Patients will receive a ‘patient guide' from their healthcare professional which they should read carefully along with the package leaflet.
Lithuanian: Iš savo sveikatos priežiūros specialisto pacientai gaus vadinamąjį paciento vadovą, kurį kartu su pakuotės lapeliu jie turėtų atidžiai perskaityti.
English: Before you use Suliqua be clear on how many dose steps you require.
Lithuanian: Prieš vartodami Suliqua, išsiaiškinkite, kiek dozės padalų jums reikia švirkštis.
English: • You must therefore not use the pens interchangeably as you could receive too much or too little lixisenatide and this could disrupt the control of your blood sugar levels.
Lithuanian: • Todėl šių švirkštiklių negalima naudoti pakaitomis, nes galite susišvirkšti per daug arba pernelyg mažai liksisenatido, todėl gali sutrikti cukraus kiekio kraujyje kontrolė.
English: • When starting Suliqua and in the weeks thereafter you should measure your blood sugar levels more frequently than usual.
Lithuanian: • Pradedant vartoti Suliqua ir vėliau kelias savaites cukraus kiekį kraujyje reikia matuoti dažniau, nei įprastai.
English: • Ensure that patients and their caretakers are adequately informed on how to use their medicine.
Lithuanian: • Pasirūpinkite, kad pacientai ir juos slaugantys asmenys būtų tinkamai informuoti apie tai, kaip vartoti jiems paskirtą vaistą.
English: • Explain the design and features of the pen to the patient and if the patient has been transferred from another pen device, highlight the differences in design between the two devices to avoid confusion (focus on colour differentiation, warning statements on carton/label).
Lithuanian: • Paaiškinkite pacientui švirkštiklio konstrukciją ir jo naudojimo ypatumus, o jeigu pacientas prieš tai naudojo kitą švirkštimo priemonę, atkreipkite jo dėmesį į šių dviejų priemonių dizaino skirtumus, kad būtų išvengta painiavos (atkreipkite dėmesį į spalvos skirtumus ir ant dėžutės ir (arba) etiketėje nurodytus įspėjimus).
English: It is used for people needing 10-40 units of insulin daily.
Lithuanian: Jis skiriamas žmonėms, kuriems reikia 10-40 vienetų insulino per parą.
English: Healthcare professionals and patients expected to use the diabetes medicine Suliqua will be given educational materials to ensure that the medicine is used correctly and prevent medication errors such as confusion between the two different strengths of the product.
Lithuanian: Sveikatos priežiūros specialistai ir pacientai, kurie turėtų vartoti vaistą nuo diabeto Suliqua, gaus šviečiamąją medžiagą, kuria siekiama užtikrinti, kad vaistas būtų vartojamas tinkamai ir būtų išvengta gydymo klaidų, pvz., nebūtų supainioti du skirtingo stiprumo preparatai.
English: To reduce the risk of medication errors, educational materials will be sent out to relevant healthcare professionals in the EU where the product is marketed, to raise awareness about the differences between the two pens, the way the dose is expressed and how to use the medicine correctly.
Lithuanian: Siekiant sumažinti gydymo klaidų pavojų, tose ES valstybėse narėse, kuriose prekiaujama šiuo vaistiniu preparatu, atitinkamiems sveikatos priežiūros specialistams bus išsiųsta šviečiamoji medžiaga, siekiant didinti informuotumą apie šių dviejų švirkštiklių skirtumus, taip pat apie tai, kokiais vienetais vaisto dozė išreikšta ir kaip tinkamai vartoti šį vaistą.
English: Pharmacists should also check that patients have been trained on how to use the pen.
Lithuanian: Vaistininkai taip pat turėtų pasitikslinti, ar pacientai išmokyti, kaip naudoti švirkštiklį.
English: • Patients who are blind or with poor vision must be instructed to always get assistance from another person who has good vision and is trained in using the Suliqua pen device.
Lithuanian: • Akliems ar prastai matantiems pacientams būtina nurodyti, kad jiems visada turi padėti kitas gerai matantis ir naudoti Suliqua švirkštimo priemonę išmokytas asmuo.
English: Suliqua is available in two different pens:
Lithuanian: Suliqua tiekiamas dviejuose skirtinguose švirkštikliuose:
English: Healthcare professionals should ensure that they train their patients on how to use Suliqua correctly.
Lithuanian: Sveikatos priežiūros specialistai turėtų užtikrinti, kad jų pacientai būtų išmokyti, kaip tinkamai vartoti Suliqua.
English: • Suliqua is supplied in a pre-filled pen and must only be used with this device.
Lithuanian: • Suliqua tiekiamas užpildytame švirkštiklyje ir jis turi būti vartojamas naudojant būtent šį prietaisą.
English: It is used together with diabetes medicines taken by mouth in adults whose blood glucose (sugar) levels are not satisfactorily controlled by metformin alone or metformin combined with either a glucose-lowering medicine or insulin.
Lithuanian: Kartu su geriamaisiais vaistais nuo diabeto jis skiriamas suaugusiesiems, kuriems nepakanka vieno metformino arba metformino ir gliukozės kiekį mažinančio vaisto ar insulino derinio gliukozės (cukraus) kiekiui kraujyje kontroliuoti.
English: Your healthcare professional will train you on how to use the pen.
Lithuanian: Jūsų sveikatos priežiūros specialistas išmokys jus, kaip naudoti švirkštiklį.
English: This could lead to fluctuations in blood glucose control.
Lithuanian: Dėl to gali pradėti svyruoti gliukozės kiekis paciento kraujyje.
English: • Read the instructions in your package leaflet carefully before using your medicine.
Lithuanian: • Prieš vartodami vaistą, atidžiai perskaitykite pakuotės lapelyje pateiktus nurodymus.
English: • Because the two pens contain different concentrations of lixisenatide, the dose step of one pen is not equivalent to the dose step of the other.
Lithuanian: • Kadangi skiriasi šiuose dviejuose švirkštikliuose esančio liksisenatido koncentracija, vieno švirkštiklio dozės padala nėra tolygi kito švirkštiklio dozės padalai.
English: • Suliqua is supplied in two pre-filled pens:
Lithuanian: • Suliqua tiekiamas dviejuose užpildytuose švirkštikliuose:
English: • Explain to your patient that the dose counter of the pen device shows the number of dose steps to be injected.
Lithuanian: • Paaiškinkite savo pacientui, kad švirkštimo priemonės dozės skaitiklis rodo, kiek dozės padalų bus sušvirkšta.
English: It is available as a solution for injection in pre-filled pens.
Lithuanian: Jis tiekiamas užpildytuose švirkštuose injekcinio tirpalo forma.
English: • As for similar medicines containing insulin with a non-insulin medicine, the dose is expressed in dose steps.
Lithuanian: • Kaip ir panašių vaistų, kurių sudėtyje yra insulino ir neinsulininio vaisto, atveju, Suliqua dozė išreikšta dozės padalomis.